aon glp-1 How GLP-1s are Reshaping Food Buying Behavior Aon study: GLP-1 medications for

64% below iron RDA, 72% below calcium RDA, only 1.4% met vitamin D recommendations

Overview on biological glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) effects at the organ/tissue level.

Glucagon-like peptide-1 receptor agonists (GLP-1RAs), established therapies for type 2 diabetes and obesity, are increasingly recognized for their potential in neurodegenerative diseases

Background Globally, obesity has emerged as a significant public health concern, imposing detrimental impacts on human health

Both glucagon-like peptide-1 receptor agonists (GLP-1RA) and sodium-glucose cotransporter-2 (SGLT-2) inhibitors can reduce CV risk in patients with T2D, and both are recommended by the American Diabetes Association to reduce the risk of major cardiovascular events (MACE)

Alhazmi A & le Roux CW